Applied Clinical Trials-05-01-2023

Even with exciting advancements, stakeholders must remain diligent in choosing data platforms.

The value of electronic patient-reported outcomes data in this disease setting.

Senior leaders gather to share insights on the increased investment in real-world data to boost the quality and efficiency of drug development—as the industry begins to more widely embrace evidence of proven outcomes in aiding approaches in clinical trial design, patient engagement, regulatory decision-making, and other areas.

Examining the two areas of weakness cited in FDA draft guidance.

‘No longer just a cool technology,’ efforts to validate these signals are evolving.

Remembering Steve Raymond, PhD, "the Godfather of ePRO."

Cristina Varner, LUTCF, ARM, SVP/national life science and digital health & telemedicine practice leader at insurance brokerage Newfront explains the nuances of insuring clinical trials in today's growing digital health climate and the newer risks in areas such as cybersecurity that developers are facing.

Insights from recent industry events clear path for companies to identify how their internal practices could be harming the environment.

Grading the government’s formal response to reform efforts hopeful of boosting UK’s sagging global standing in drug development.

Impact areas that will be closely watched during phase-out include drug testing and authorization, telehealth, and patient access.